Arca
Skip to content
Tools
Tools

Emphysema

Drug research and approvals for emphysema: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 18, 2026, 66 studies of emphysema are recruiting on ClinicalTrials.gov, Health Canada has authorized 3 drug trials for it since 2013, FDA has 1 approved and 6 open orphan designations naming it, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 66
  • Trials authorized in Canada: 3
  • FDA orphan approvals: 1
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 66 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

12 approved, 1 in phase 3, 7 in phase 2; from ChEMBL's drug indications, furthest stage reached for this condition

Approved: Salmeterol, Arformoterol, Formoterol, Budesonide, Fluticasone propionate, Aclidinium, Tiotropium, Ipratropium, Vilanterol, Indacaterol, Umeclidinium, Olodaterol

Basiliximab
Phase 3 Interleukin-2 receptor inhibitor
Doxycycline anhydrous
Phase 2 Matrix metalloproteinase 7 inhibitor
Ibuprofen
Phase 2 Cyclooxygenase inhibitor
Isotretinoin
Phase 2 Retinoic acid receptor agonist
Tretinoin
Phase 2 Retinoic acid receptor agonist
Sildenafil
Phase 2 Phosphodiesterase 5A inhibitor
Belimumab
Phase 2 Tumor necrosis factor ligand superfamily member 13B inhibitor

How Its Trials Ended

323 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 84 whose ending is known, 37% met their primary endpoint, 6% missed it and 57% stopped early.

  • Completed, result not reported13141%
  • Ongoing6119%
  • Status unknown4715%
  • Stopped: other or unclear3310%
  • Met its primary endpoint3110%
  • Stopped: enrollment or feasibility82%
  • Missed its primary endpoint52%
  • Stopped: sponsor or business decision31%
  • Stopped: safety21%
  • Stopped: funding21%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Feb 1, 2021Characterizing mmp12 in sputum and its relationship to emphysema and inflammatory endotypesHyperpolarized XENON-129St. Joseph'S Healthcare HamiltonPending
Nov 30, 2015An open-label, multicenter study to evaluate the long-term safety of weekly intravenous alpha1-proteinase inhibitor (human), modified process 60 mg/kg in…Prolastin-cGrifolsOngoing
Sep 18, 2013"a randomized, double-blind, placebo-controlled study to assess the efficacy and safety of two dose regimens (60mg/kg and 120mg/kg) of weekly intravenous…Prolastin-cGrifolsClosed

FDA Orphan Designations

Approved first, then open designations, newest first
Dec 2, 1987ProlastinFor chronic replacement therapy of individuals having congenital deficiency of alpha1- proteinase inhibitor with clinically demonstrable…Bayer CorporationApproved
Jan 18, 2017Hyaluronic acidTreatment of emphysema due to alpha1-antitrypsin deficiency.Gerard M. Turino, MDDesignated
Jan 29, 2010alpha1 proteinase inhibitor (human)Treatment of emphysema secondary to congenital alpha1-antitrypsin deficiency.Grifols Therapeutics, Inc.Designated
Mar 19, 2002Hyaluronic acidTreatment of emphysema in patients due to alpha-1 antitrypsin deficiencyCoTherixDesignated
Aug 28, 2001Recombinant human alpha-1 antitrypsin (rAAT)To delay progression of chronic obstructive pulmonary disease resulting from AAT deficiency-mediated emphysema and bronchiectasisAiroMedica LLCDesignated
Nov 24, 1999Alpha1-proteinase inhibitor (human)For slowing the progression of emphysema in alpha1-antitrypsin deficient patients.CSL Behring L.L.C.Designated
May 19, 1999Transgenic human alpha 1 antitrypsinTreatment of emphysema secondary to alpha 1 antitrypsin deficiency.PPL Therapeutics (Scotland) LimitedDesignated

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Aug 20, 2015Respreezaalpha1-proteinase inhibitor (human)CSL Behring GmbHEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.